Okay, how many reps and managers should we get rid of?

[Anonymous]

Too many reps and way too many managers. Managers should have 12-15 reports. Want to save money get rid of these highly paid idiots.

 

[Anonymous]

Is it true that MSK will be eliminated and integrated into neuroscience by year end? What amazes me is that it takes two divisions to sell one product. Why neuroscience can't talk to physicians about Cymbalta for DPNP, depression, pain etc. ...every indication. Don't you think with VBS physicians only want to talk with ONE rep.About all of the indications of a given product. It is just plain stupidity! That is why we don't need this division,

 

[Anonymous]

5501.

 

[Anonymous]

A recent six sigma project revealed that early phase testing of drugs in sales reps was far cheaper than using lab rats. Therefore, I have made the executive decision to retain our entire sales force and use them for experimentation to progress our pipeline forward. FIPNET has guided me to this decision, therefore it is good. $$JL$$

 

[Anonymous]

Project Symphony

 

[Anonymous]

Is it true that MSK will be eliminated and integrated into neuroscience by year end? What amazes me is that it takes two divisions to sell one product. Why neuroscience can't talk to physicians about Cymbalta for DPNP, depression, pain etc. ...every indication. Don't you think with VBS physicians only want to talk with ONE rep.About all of the indications of a given product. It is just plain stupidity! That is why we don't need this division,

MSK gone 2012

 

[Anonymous]

If you look at where Cymbalta is growing, it is in the pain market not mood. Maybe we should get rid of neuroscience reps. Do we really need that many reps to sell Cymbalta and Strattera.

 

[Anonymous]

We could easily get rid of 1/3 or every Lilly sales force and not miss a beat. Way too many reps, dms and directors for the job that needs to be done.

 

[Anonymous]

If you look at where Cymbalta is growing, it is in the pain market not mood. Maybe we should get rid of neuroscience reps. Do we really need that many reps to sell Cymbalta and Strattera.

Come on folks!!!!! We only need one division selling Cymbalta!!!! The rep can converse with physicians on both the mood AND pain indication!!!!! It's like asking how many reps does it take to screw in a lightbulb? Apparently at Lilly it takes two!!! BIG waste of money! How does IMS data distinguish pain from mood? It doesn't!!! Double compensation and bonus for neuroscience/MSK!! Also additional expense for Lilly. Does this really make sense? If neuroscience division can sell Cialis and Axiron then we can also take on Evista. We have in the past and we can do it again until the patent expires.

 

[Anonymous]

Come on folks!!!!! We only need one division selling Cymbalta!!!! The rep can converse with physicians on both the mood AND pain indication!!!!! It's like asking how many reps does it take to screw in a lightbulb? Apparently at Lilly it takes two!!! BIG waste of money! How does IMS data distinguish pain from mood? It doesn't!!! Double compensation and bonus for neuroscience/MSK!! Also additional expense for Lilly. Does this really make sense? If neuroscience division can sell Cialis and Axiron then we can also take on Evista. We have in the past and we can do it again until the patent expires.

This is a 15 year old argument. Do WE need all of these reps? Hell no, not now. But we have needed them in the past, just because our competitors have had a ton of reps. It's the old "share of voice" data that was so important. But now that every pharma company seems to be downsizing their sales force, we are doing so also. By Q1-12, there will be only 1 sales force selling Cymbalta, and it will be a smaller sales force doing so. Get ready.

 

[Anonymous]

Q1 October 2012 or January 2012. One division promoting Cymbalta. What happens with psych reps and MSK neuro reps as well as PC reps??